PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV · News & media

Hims & Hers Stops Selling Wegovy Copycat Weight-Loss Pill

News & media2:53Feb 2026

Today’s cheapest Wegovy$208/mo at Sesame Care, an average: a $59/mo subscription billed $708 once a year, with medication billed monthly.Compare all Wegovy prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. Not from the video’s creator.

Our summary

The anchor asks Bloomberg Intelligence senior pharmaceutical analyst the speaker, whose surname is not clear in the captions, for the latest. The analyst says the issue is not about a company responding to regulators. In his view it is a matter of law: a drug still covered by a patent in the market where it is sold cannot be copied, whether or not the copy is safe.

Published by Bloomberg Television on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

He contrasts this with generic drug makers, which he says run their own trials, compare against the product they want to compete with, and then seek FDA approval. A company making the drugs in a pharmacy and selling them to patients, he says, is not right, and he sees some logic returning to the system.

The conversation then turns to Eli Lilly shares outperforming Novo even though Novo created this drug class. The analyst gives two reasons for Lilly's lead. First, Lilly had a good injection pen from its diabetes business. Second, it took a gamble on a molecule that acts on both GLP-1 and GIP, which he says nobody expected to perform as well as it did. He says this drug beat Wegovy in a head-to-head trial with higher efficacy, better weight loss and a similar side effect profile. He adds that Lilly has sold to mass-market settings while Novo mostly sold to diabetes specialists, and that Novo now has a new head of U.S. operations, whose impact remains to be seen.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:31 The analyst says copying a drug still under patent is not allowed, whether or not the copy is safe.
  2. 1:04 He contrasts generic makers, which run trials and seek FDA approval, with a company making the drugs in a pharmacy and selling them to patients.
  3. 1:36 He says Lilly's lead came from a good injection pen and a gamble on a drug acting on both GLP-1 and GIP.
  4. 2:10 According to the analyst, that Lilly drug beat Wegovy in a head-to-head trial with better weight loss and a similar side effect profile.
  5. 2:41 He notes Lilly sold to mass-market settings while Novo mostly sold to diabetes specialists, and Novo has a new U.S. head.

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Wegovy

Questions this video answers

How is a generic drug different from a pharmacy-made copy, according to this analyst?

He says generic companies run a set of trials, compare against the product they want to compete with, and then go to the FDA for approval. He contrasts that with a company making drugs in a pharmacy and selling them directly to people.

Why has Eli Lilly outperformed Novo Nordisk in GLP-1 drugs?

The analyst cites Lilly's good injection pen and its gamble on a molecule acting on both GLP-1 and GIP. He says that drug beat Wegovy in a head-to-head trial and that Lilly's experience selling to mass-market settings also helped.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • TrumpRx GLP-1 prices: what Wegovy, Zepbound, Ozempic and Foundayo cost there

    TrumpRx.gov does not sell GLP-1s. It lists each maker's own cash price and passes you to the maker: a Novo coupon you show at the pharmacy, or LillyDirect for Lilly's drugs. On 8 October 2026 it showed the Wegovy pill at $149 to $299 a month by dose, the Wegovy pen and Ozempic at $199 for two new-patient fills then $349, Zepbound at $299 to $449 and Foundayo at $149 to $299. Those match what NovoCare and LillyDirect publish, and they are cash only.

  • Is Hims legit? What its GLP-1 program costs, what reviews say, and its FDA record

    Yes. Hims & Hers is a real, licensed telehealth company, and as of October 2026 its weight-loss program sells FDA-approved brand-name GLP-1s: the Wegovy pill starts at $149 a month for the medication, plus a membership of $39 for the first month and $149 a month after, so about $298 a month from month two. It scores 2.9 on Trustpilot across 9,517 reviews, and FDA sent it a warning letter in September 2025 over compounded semaglutide marketing claims.

  • LillyDirect vs NovoCare Pharmacy: every self-pay price by dose, the refill rules, and who can use them

    LillyDirect sells Zepbound vials and KwikPens from $299 a month at 2.5 mg, $399 at 5 mg and $449 at every higher dose, but only if each refill is bought within 45 days of the last delivery; miss it and 10 to 15 mg costs $699. NovoCare Pharmacy sells every Wegovy pen dose for $349 ($199 for a new patient's first two boxes), Wegovy HD for $399, and the Wegovy pill from $149. Both are cash only, and neither counts toward your deductible.

Next steps

Wegovy prices

Insurance

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV